Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies
Authors
Keywords
-
Journal
DRUGS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-16
DOI
10.1007/s40265-019-01163-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
- (2019) Ian W. Flinn et al. BLOOD
- Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
- (2019) Peter Hillmen et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
- (2018) Steven Coutre et al. BLOOD
- Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
- (2018) Matthew S. Davids et al. CLINICAL CANCER RESEARCH
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- MCL-1 is a prognostic indicator and drug target in breast cancer
- (2018) Kirsteen J. Campbell et al. Cell Death & Disease
- Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
- (2018) Bibi Kulsoom et al. Cancer Management and Research
- Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
- (2018) S de Vos et al. ANNALS OF ONCOLOGY
- Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
- (2018) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Bcl-2 for the treatment of multiple myeloma
- (2018) Cyrille Touzeau et al. LEUKEMIA
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
- (2018) Arnon P. Kater et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia
- (2018) Piers Blombery et al. Cancer Discovery
- Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues
- (2018) Kate E. Grimm et al. Annals of Diagnostic Pathology
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study
- (2017) John F Seymour et al. LANCET ONCOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax
- (2016) Joan Montero et al. Cancer Discovery
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy
- (2015) Joan Montero et al. CELL
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
- (2015) S M Matulis et al. LEUKEMIA
- Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia
- (2015) Jennifer R. Brown et al. LEUKEMIA & LYMPHOMA
- A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
- (2015) Thomas J. Kipps et al. LEUKEMIA & LYMPHOMA
- Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer
- (2015) Haichao Zhang et al. Molecular Cancer
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies
- (2015) Jane Huang et al. Expert Review of Hematology
- Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
- (2014) V. Fresquet et al. BLOOD
- Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
- (2014) X Niu et al. LEUKEMIA
- Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition
- (2014) M R Sapienza et al. LEUKEMIA
- Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity
- (2014) Zhi-Fu Tao et al. ACS Medicinal Chemistry Letters
- Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells
- (2013) S. G. Katz et al. BLOOD
- Reprogramming cell death: BCL2 family inhibition in hematological malignancies
- (2013) Lydia Scarfò et al. IMMUNOLOGY LETTERS
- BH3 profiling in whole cells by fluorimeter or FACS
- (2013) Jeremy Ryan et al. METHODS
- Structure-guided design of a selective BCL-XL inhibitor
- (2013) Guillaume Lessene et al. Nature Chemical Biology
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations
- (2012) J. Edelmann et al. BLOOD
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
- (2012) Thanh-Trang Vo et al. CELL
- A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers
- (2012) James L. LaBelle et al. JOURNAL OF CLINICAL INVESTIGATION
- ABT-737 is highly effective against molecular subgroups of multiple myeloma
- (2011) L. Bodet et al. BLOOD
- Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas
- (2011) Elizabeth A. Brem et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1lowProfile and Synergizes with Other Antineoplastic Agents
- (2011) Cyrille Touzeau et al. CLINICAL CANCER RESEARCH
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1
- (2011) Yair Herishanu et al. LEUKEMIA & LYMPHOMA
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- (2011) Ingrid E. Wertz et al. NATURE
- Tyrosine kinase expression profile in clear cell renal cell carcinoma
- (2011) Turang E. Behbahani et al. WORLD JOURNAL OF UROLOGY
- B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma
- (2010) Matija Snuderl et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
- (2010) L Bodet et al. BRITISH JOURNAL OF CANCER
- Bcl-2 Family Proteins as Therapeutic Targets
- (2010) Peter E. Czabotar et al. CURRENT PHARMACEUTICAL DESIGN
- Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
- (2010) Laura Bonapace et al. JOURNAL OF CLINICAL INVESTIGATION
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
- (2009) Susan O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- RNA Silencing of Mcl-1 Enhances ABT-737-Mediated Apoptosis in Melanoma: Role for a Caspase-8-Dependent Pathway
- (2009) Angela M. Keuling et al. PLoS One
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
- (2008) S. M. O'Brien et al. BLOOD
- Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
- (2008) Barbara Pro et al. BRITISH JOURNAL OF HAEMATOLOGY
- Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell
- (2008) San-Hua Wei et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax)
- (2008) M. Konopleva et al. CANCER RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies
- (2008) A. D. Schimmer et al. CLINICAL CANCER RESEARCH
- Mechanism of Synergy of N-(4-Hydroxyphenyl)Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation
- (2008) Min H. Kang et al. JNCI-Journal of the National Cancer Institute
- ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
- (2008) Scott Ackler et al. MOLECULAR CANCER THERAPEUTICS
- Bcl-2 family proteins and cancer
- (2008) K W Yip et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search